La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AIM Vaccine Gestione

Gestione criteri di controllo 3/4

AIM Vaccine's Il CEO è Yan Zhou, nominato in Sep2020, e ha un mandato di 3.92 anni. la retribuzione annua totale è CN¥ 2.18M, composta da 86.5% di stipendio e 13.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 16.62% delle azioni della società, per un valore di HK$ 1.16B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.4 anni e 4 anni.

Informazioni chiave

Yan Zhou

Amministratore delegato

CN¥2.2m

Compenso totale

Percentuale dello stipendio del CEO	86.5%
Mandato del CEO	3.9yrs
Proprietà del CEO	16.6%
Durata media del management	3.4yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

Aug 24

It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

May 29

Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

Jun 09

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Yan Zhou rispetto agli utili di AIM Vaccine?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	CN¥2m	CN¥2m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥913m
Jun 30 2023	n/a	n/a	-CN¥525m
Mar 31 2023	n/a	n/a	-CN¥422m
Dec 31 2022	CN¥2m	CN¥2m	-CN¥320m
Dec 31 2021	CN¥899m	CN¥1m	-CN¥693m

Compensazione vs Mercato: La retribuzione totale di Yan ($USD 304.73K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 469.55K ).

Compensazione vs guadagni: La retribuzione di Yan è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Yan Zhou (57 yo)

3.9yrs

Mandato

CN¥2,175,000

Compensazione

Mr. Yan Zhou is Executive Chairman and Chief Executive Officer of AIM Vaccine Co., Ltd. September 2020. He has served as a Director of AIM Vaccine Co., Ltd.since May 2015 and was re-designated as an execu...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Yan Zhou	Executive Chairman & CEO	3.9yrs	CN¥2.18m	16.62% CN¥ 940.2m
Xin Zhou	Executive Vice-Chairman of the Board	11.3yrs	Nessun dato	3.3% CN¥ 186.8m
Wen Guan	Vice-Chairman of the Board & Executive President	3.5yrs	CN¥2.23m	Nessun dato
Shaojun Jia	COO, Executive President & Executive Director	3.5yrs	CN¥2.43m	0.84% CN¥ 47.4m
Lixin Niu	Chief Financial Officer	8.8yrs	Nessun dato	Nessun dato
Ling Liu	Secretary & Chief Investment Officer	8.8yrs	Nessun dato	Nessun dato
Zhang Fan	Chief Research Officer	3.4yrs	Nessun dato	Nessun dato
Meng Li	Chief Quality Officer	2.3yrs	Nessun dato	Nessun dato
Zhou Wenjuan	Chief Public Affairs Officer	2.4yrs	Nessun dato	Nessun dato
Lin Zhenyu	Chief Marketing Officer	2.4yrs	Nessun dato	Nessun dato
Wing Chi Lam	Joint Company Secretary	3.2yrs	Nessun dato	Nessun dato

3.4yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di 6660 è considerato esperto (durata media dell'incarico 3.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yan Zhou	Executive Chairman & CEO	9.3yrs	CN¥2.18m	16.62% CN¥ 940.2m
Xin Zhou	Executive Vice-Chairman of the Board	11.3yrs	Nessun dato	3.3% CN¥ 186.8m
Wen Guan	Vice-Chairman of the Board & Executive President	3.5yrs	CN¥2.23m	Nessun dato
Shaojun Jia	COO, Executive President & Executive Director	7yrs	CN¥2.43m	0.84% CN¥ 47.4m
Ker Wei Pei	Independent Non-Executive Director	3.9yrs	CN¥300.00k	Nessun dato
Tingfeng Song	Chairman of The Supervisory Committee	3.5yrs	Nessun dato	Nessun dato
Hui Ouyang	Independent Non-Executive Director	3.3yrs	CN¥300.00k	Nessun dato
Aijun Wang	Non-Executive Director	6.9yrs	Nessun dato	4.13% CN¥ 233.5m
Xiaoguang Guo	Independent Non-Executive Director	3.5yrs	CN¥300.00k	Nessun dato
Jie Zhou	Non-Executive Director	9.3yrs	Nessun dato	3.3% CN¥ 186.8m
Jichen Zhao	Non-Executive Director	4.2yrs	Nessun dato	Nessun dato
Jie Wen	Independent Non-Executive Director	3.3yrs	CN¥300.00k	Nessun dato

4.0yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6660 sono considerati esperti (durata media dell'incarico 4 anni).

AIM Vaccine Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

AIM Vaccine Co., Ltd., Annual General Meeting, May 20, 2024

AIM Vaccine Co., Ltd. Announces Executive Changes

AIM Vaccine Co., Ltd. Announces Board Appointments

Executive Chairman & CEO recently bought HK$249k worth of stock

Executive Chairman & CEO recently bought HK$716k worth of stock

Executive Chairman & CEO recently bought HK$525k worth of stock

Recent updates

Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

AIM Vaccine Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Aim Vaccine Co., Ltd. Announces Submission of Pre-Applications for Clinical Trials for Two mRNA Vaccines of Respiratory Syncytial Virus (RSV) And Shingles/Herpes Zoster of Aim Vaccine

It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

AIM Vaccine Co., Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: CN¥1.07 loss per share (vs CN¥0.27 loss in FY 2022)

AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells)

AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine

New minor risk - Financial data availability

AIM Vaccine Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

New minor risk - Share price stability

AIM Vaccine Co., Ltd. Announces Completion of Application for Marketing of 13-Valent Pneumonia Conjugate Vaccine, Iterative Serum-Free Rabies Vaccine and 23-Valent Pneumonia Polysaccharide Vaccine

AIM Vaccine Co., Ltd. Submits the Pre- Application for Marketing Registration for Its 13-Valent Pneumonia Conjugate Vaccine

AIM Vaccine Co., Ltd. Announces Executive Changes

AIM Vaccine Co., Ltd. Announces Board Appointments

Executive Chairman & CEO recently bought HK$249k worth of stock

Executive Chairman & CEO recently bought HK$716k worth of stock

Executive Chairman & CEO recently bought HK$525k worth of stock

Executive Chairman & CEO recently bought HK$1.3m worth of stock

Aim Vaccine Co., Ltd. Announces Phase III Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Is Near Completion and Statistical Unblinding Will Commence Soon

AIM Vaccine Co., Ltd. Announces Completion of Full Course of Vaccination in Subjects of Phase III Clinical Trial of 23-Valent Pneumococcal Polysaccharide Vaccine

New minor risk - Share price stability

Aim Vaccine Co., Ltd. Announces Phase III Clinical Trial of Serum-Free Rabies Vaccine Acciedated Satisfactory Phase Results

AIM Vaccine Co., Ltd. Announces Initiation of Randomized, Blinded and Compatible Vaccine-Controlled Phase III Clinical Trial of 23-Valent Pneumococcal Polysaccharide Vaccine

AIM Vaccine Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

AIM Vaccine Co., Ltd. Announces Bivalent mRNA Vaccine Against COVID-19 Variants Delta and OmicronBA.5 Obtains Clinical Trial Approval from National Medical Products Administration of China

AIM Vaccine Co., Ltd. Announces PRC National Medical Products Administration Accepts Application for Clinical Trial of Human Rabies mRNA Vaccine Against Rabies Virus

Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

AIM Vaccine Co., Ltd. Announces Major Results of a Study on Protective Efficacy of COVID-19 Variant Omicron BA.5 mRNA Vaccine LVRNA012

Full year 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.60 loss in FY 2021)

Aim Vaccine Co., Ltd. Announces That Mrna Covid-19 Vaccine Candidates Against Covid-19Variants and Original Strain Obtained Clinicaltrial Approvals in Pakistan

Less than half of directors are independent

AIM Kanghuai Biopharmaceutical (Jiangsu) Co., Ltd. Obtains Clinical Trial Approval for EV71-CA16 Bivalent HFMD Vaccine Candidate Issued by the Center for Drug Evaluation of National Medical Products Administration

AIM Vaccine Co., Ltd. has completed an IPO in the amount of HKD 156.97824 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media